Transgene regulation using the tetracycline-inducible TetR-KRAB system after AAV-mediated gene transfer in rodents and nonhuman primates

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Le Guiner, Caroline ^a   Stieger, Knut ^a,b   Toromanoff, Alice ^a   Guilbaud, Mickaël ^a   Mendes Madeira, Alexandra ^a   Devaux, Marie ^a   Guigand, Lydie ^c   Cherel, Yan ^c   Moullier, Philippe ^a,d   Rolling, Fabienne ^a   Adjali, Oumeya ^a  

^a INSERM   (France)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c LUNAM UNIVERSITÉ   (France)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; KRUPPEL LIKE FACTOR; REGULATOR PROTEIN; TETR PROTEIN; TETRACYCLINE; UNCLASSIFIED DRUG; DOXYCYCLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE EXPRESSION REGULATION; GENETIC REGULATION; GENETIC TRANSDUCTION; HUMORAL IMMUNITY; IMMUNOGENICITY; MACACA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; RAT; TRANSCRIPTION REGULATION; TRANSGENE; TRANSLATION REGULATION; VIRAL GENE DELIVERY SYSTEM; ADMINISTRATION AND DOSAGE; ANIMAL; C57BL MOUSE; CELLULAR IMMUNITY; CLASSIFICATION; DEPENDOPARVOVIRUS; DRUG EFFECTS; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; RETINA; SKELETAL MUSCLE; VIROLOGY; WISTAR RAT;

PRIMATES; RODENTIA;

ANIMALS; DEPENDOVIRUS; DOXYCYCLINE; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MACACA; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; RATS; RATS, WISTAR; RETINA; TETRACYCLINE; TRANSGENES;

EID: 84907588617     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102538     Document Type: Article

References (46)

1. Monahan PE, Samulski RJ (2000) Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 6: 433-440.
2. Snyder RO (1999) Adeno-associated virus-mediated gene delivery. J Gene Med 1: 166-175.
3. Penaud-Budloo M, Le Guiner C, Nowrouzi A, Toromanoff A, Cherel Y, et al. (2008) Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol 82: 7875-7885.
4. Nowrouzi A, Penaud-Budloo M, Kaeppel C, Appelt U, Le Guiner C, et al. (2012) Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther 20: 1177-1186.
5. Bryant LM, Christopher DM, Giles AR, Hinderer C, Rodriguez JL, et al. (2013) Lessons learned from the clinical development and market authorization of Glybera. Human gene therapy Clinical development 24: 55-64.
6. Melchiorri D, Pani L, Gasparini P, Cossu G, Ancans J, et al. (2013) Regulatory evaluation of Glybera in Europe - two committees, one mission. Nature reviews Drug discovery 12: 719.
7. Gossen M, Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 89: 5547-5551.
8. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, et al. (1995) Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769.
9. Rivera VM, Clackson T, Natesan S, Pollock R, Amara JF, et al. (1996) A humanized system for pharmacologic control of gene expression. Nat Med 2: 1028-1032.
10. Rivera VM, Ye X, Courage NL, Sachar J, Cerasoli F Jr, et al. (1999) Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci U S A 96: 8657-8662.
11. Toniatti C, Bujard H, Cortese R, Ciliberto G (2004) Gene therapy progress and prospects: transcription regulatory systems. Gene therapy 11: 649-657.
12. Vilaboa N, Voellmy R (2006) Regulatable gene expression systems for gene therapy. Current gene therapy 6: 421-438.
13. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Joussemet B, et al. (2004) Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle. Mol Ther 9: 410-418.
14. Favre D, Blouin V, Provost N, Spisek R, Porrot F, et al. (2002) Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol 76: 11605-11611.
15. Folliot S, Briot D, Conrath H, Provost N, Cherel Y, et al. (2003) Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single type 2 adeno-associated viral vector. The journal of gene medicine 5: 493-501.
16. Stieger K, Mendes-Madeira A, Meur GL, Weber M, Deschamps JY, et al. (2007) Oral administration of doxycycline allows tight control of transgene expression: a key step towards gene therapy of retinal diseases. Gene Ther 14: 1668-1673.
17. Lebherz C, Auricchio A, Maguire AM, Rivera VM, Tang W, et al. (2005) Longterm inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Human gene therapy 16: 178-186.
18. Stieger K, Le Meur G, Lasne F, Weber M, Deschamps JY, et al. (2006) Longterm doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Molecular therapy: the journal of the American Society of Gene Therapy 13: 967-975.
19. Toromanoff A, Adjali O, Larcher T, Hill M, Guigand L, et al. (2010) Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Molecular therapy: the journal of the American Society of Gene Therapy 18: 151-160.
20. Deuschle U, Meyer WK, Thiesen HJ (1995) Tetracycline-reversible silencing of eukaryotic promoters. Mol Cell Biol 15: 1907-1914.
21. Margolin JF, Friedman JR, Meyer WK, Vissing H, Thiesen HJ, et al. (1994) Kruppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci U S A 91: 4509-4513.
22. Moosmann P, Georgiev O, Thiesen HJ, Hagmann M, Schaffner W (1997) Silencing of RNA polymerases II and III-dependent transcription by the KRAB protein domain of KOX1, a Kruppel-type zinc finger factor. Biol Chem 378: 669-677.
23. Friedman JR, Fredericks WJ, Jensen DE, Speicher DW, Huang XP, et al. (1996) KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes & development 10: 2067-2078.
24. Wiznerowicz M, Trono D (2003) Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 77: 8957-8961.
25. Marquis J, Kampfer SS, Angehrn L, Schumperli D (2009) Doxycyclinecontrolled splicing modulation by regulated antisense U7 snRNA expression cassettes. Gene Ther 16: 70-77.
26. Szulc J, Wiznerowicz M, Sauvain MO, Trono D, Aebischer P (2006) A versatile tool for conditional gene expression and knockdown. Nat Methods 3: 109-116.
27. Bulliard Y, Wiznerowicz M, Barde I, Trono D (2006) KRAB can repress lentivirus proviral transcription independently of integration site. J Biol Chem 281: 35742-35746.
28. Barde I, Laurenti E, Verp S, Groner AC, Towne C, et al. (2009) Regulation of episomal gene expression by KRAB/KAP1-mediated histone modifications. J Virol 83: 5574-5580.
29. Pichard V, Aubert D, Boni S, Battaglia S, Ivacik D, et al. (2012) Specific micro RNA-regulated TetR-KRAB transcriptional control of transgene expression in viral vector-transduced cells. PloS one 7: e51952.
30. Li X, Zhao X, Fang Y, Jiang X, Duong T, et al. (1998) Generation of destabilized green fluorescent protein as a transcription reporter. The Journal of biological chemistry 273: 34970-34975.
31. Weber M, Rabinowitz J, Provost N, Conrath H, Folliot S, et al. (2003) Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Molecular therapy: the journal of the American Society of Gene Therapy 7: 774-781.
32. Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, et al. (2013) Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPL(S447X)) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 20: 361-369.
33. Bohl D, Salvetti A, Moullier P, Heard JM (1998) Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 92: 1512-1517.
34. Le Guiner C, Stieger K, Snyder RO, Rolling F, Moullier P (2007) Immune responses to gene product of inducible promoters. Curr Gene Ther 7: 334-346.
35. Yang Z, Wen HJ, Minhas V, Wood C (2009) The zinc finger DNA-binding domain of K-RBP plays an important role in regulating Kaposi's sarcomaassociated herpesvirus RTA-mediated gene expression. Virology 391: 221-231.
36. Latta-Mahieu M, Rolland M, Caillet C, Wang M, Kennel P, et al. (2002) Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Human gene therapy 13: 1611-1620.
37. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, et al. (2005) Longterm pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105: 1424-1430.
38. Ye X, Rivera VM, Zoltick P, Cerasoli F Jr, Schnell MA, et al. (1999) Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283: 88-91.
39. Arruda VR, Schuettrumpf J, Herzog RW, Nichols TC, Robinson N, et al. (2004) Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 103: 85-92.
40. Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, et al. (2005) Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther 12: 1453-1464.
41. Ginhoux F, Turbant S, Gross DA, Poupiot J, Marais T, et al. (2004) HLAA-0201-restricted cytolytic responses to the rtTA transactivator dominant and cryptic epitopes compromise transgene expression induced by the tetracycline on system. Molecular therapy: the journal of the American Society of Gene Therapy 10: 279-289.
42. Toromanoff A, Cherel Y, Guilbaud M, Penaud-Budloo M, Snyder RO, et al. (2008) Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther 16: 1291-1299.
43. Mays LE, Wang L, Lin J, Bell P, Crawford A, et al. (2013) AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion and minimal MHCI upregulation on target cells. Molecular therapy: the journal of the American Society of Gene Therapy.
44. Ohshima S, Shin JH, Yuasa K, Nishiyama A, Kira J, et al. (2009) Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Molecular therapy: the journal of the American Society of Gene Therapy 17: 73-80.
45. Vandenberghe LH, Wang L, Somanathan S, Zhi Y, Figueredo J, et al. (2006) Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nature medicine 12: 967-971.
46. Rolling F, Shen WY, Tabarias H, Constable I, Kanagasingam Y, et al. (1999) Evaluation of adeno-associated virus-mediated gene transfer into the rat retina by clinical fluorescence photography. Human gene therapy 10: 641-648.